Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» J&J scuttles a $945M arthritis deal with Astellas on the eve of Phase III
J&J scuttles a $945M arthritis deal with Astellas on the eve of Phase III
J&J scuttles a $945M arthritis deal with Astellas on the eve of Phase III
Submitted by
admin
on December 2, 2014 - 9:25am
Source:
Fierce Biotech
News Tags:
JNJ
Astellas
rheumatoid arthritis
ASP015K
JAK inhibitors
Headline:
J&J scuttles a $945M arthritis deal with Astellas on the eve of Phase III
Do Not Allow Advertisers to Use My Personal information
